TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17892034

Group type: EXPERIMENTAL
Intervention: Continuous transdermal hormonal therapy with 17beta‐estradiol (0.05 mg/24 hours) and oral dydrogesterone (5 mg daily)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Continuous transdermal hormonal therapy with 17beta‐estradiol (0.05 mg/24 hours) and oral medroxyprogesterone (5 mg daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 59
Study: 15478054

Group type: EXPERIMENTAL
Intervention: End-to-end anastomosis
Number of subjects: 49
Study: 11682036

Group type: EXPERIMENTAL
Intervention: Interferon plus amantadine
Number of subjects: 143

Group type: COMPARATOR
Intervention: Interferon alone
Number of subjects: 143
Study: 9459623

Group type: EXPERIMENTAL
Intervention: Euthyroid after 6 months of methimazole
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Euthyroid at drug withdrawal
Number of subjects: 88

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Relapsing forms of disease
Number of subjects: 88
Study: 7491892

Group type: EXPERIMENTAL
Intervention: Fried onions (rich in quercetin glucosides) equivalent to 89 mg aglycone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pure quercetin rutinoside equivalent to 100 mg aglycone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pure quercetin aglycone equivalent to 100 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 9
Study: 2128072

Group type: COMPARATOR
Intervention: EDTA test
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lactulose and EDTA tests
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of EDTA and sugar tests
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lactulose-mannitol test
Number of subjects: 28
Study: 386676

Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control
Number of subjects: 290
Study: 31228675

Group type: EXPERIMENTAL
Intervention: Intravenous intralipid (2 doses of 20% solution, 4 ml diluted in 250 ml normal saline)
Number of subjects: 105
Study: 28338620

Group type: EXPERIMENTAL
Intervention: Secure and privacy-preserving navigation scheme using vehicular spatial crowdsourcing based on fog-based VANETs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryptographic primitives including Elgamal encryption algorithm, AES, randomized anonymous credentials, and group signatures
Number of subjects: 0
Study: 24742182

Group type: EXPERIMENTAL
Intervention: Acupuncture at local acupoints in combination with distal acupoint
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Acupuncture at local acupoints in combination with distal non-acupoint
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Acupuncture at local non-acupoints in combination with distal acupoint
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Acupuncture at local non-acupoints in combination with distal non-acupoint
Number of subjects: 164
Study: 22404057

Group type: EXPERIMENTAL
Intervention: pH‐stat management
Number of subjects: 9

Group type: COMPARATOR
Intervention: alpha‐stat management
Number of subjects: 9
Study: 20097934

Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapoxetine (single and multiple dosing)
Number of subjects: 0
Study: 19068724

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of epirubicin (40 mg in 40 ml saline) once every two weeks for 3 months starting one week after TURBT (Group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of epirubicin (40 mg in 40 ml saline) once every two weeks for 3 months starting 6 months after TURBT (Group B)
Number of subjects: 54
Study: 15854872

Group type: EXPERIMENTAL
Intervention: Reformulated cognitive-behavioral (RCB) treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard behavioral (SB) treatment
Number of subjects: 28
Study: 12814527

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) 3 mg vaginal pessary in two doses 6 hourly
Number of subjects: 200

Group type: COMPARATOR
Intervention: Extra-amniotic saline infusion (EASI) with simultaneous intravenous oxytocin infusion for 12 hours
Number of subjects: 200
Study: 10661762

Group type: EXPERIMENTAL
Intervention: Automated video image analysis system
Number of subjects: 110

Group type: COMPARATOR
Intervention: Normal postures (control group)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Patient postures (intervention group)
Number of subjects: 110
Study: 7577616

Group type: EXPERIMENTAL
Intervention: University hospitals (n = 13)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Major county hospitals (n = 25)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Minor county hospitals (n = 61)
Number of subjects: 574

Group type: COMPARATOR
Intervention: All hospital categories
Number of subjects: 574
Study: 2246997

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicomponent programmes including counselling and ongoing follow up and support with nicotine chewing gum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine (oral or transdermal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7425917

Group type: EXPERIMENTAL
Intervention: 8‐tenths percent tropicamide with 5% phenylephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction of the concentration of either component
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase of the tropicamide concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 drop of the optimal combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 drops of the optimal combination
Number of subjects: 0
Study: 31556165

Group type: EXPERIMENTAL
Intervention: Non-invasive prenatal diagnosis technique for spinal muscular atrophy
Number of subjects: 27
Study: 30636729

Group type: EXPERIMENTAL
Intervention: Dry needling without eliciting local twitch response (LTR)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Dry needling with eliciting local twitch response (LTR)
Number of subjects: 26
Study: 27930393

Group type: EXPERIMENTAL
Intervention: Intervention addressing fear-avoidance beliefs
Number of subjects: 240

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 240
Study: 25557838

Group type: EXPERIMENTAL
Intervention: Zanamivir (10 mg daily prophylaxis)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Trivalent split virus influenza vaccine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both zanamivir and vaccine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Exposure to family members and patients with ARI
Number of subjects: 64
Study: 24254567

Group type: EXPERIMENTAL
Intervention: In‐Out technique, with cortical fixation and Interference screw
Number of subjects: 45

Group type: COMPARATOR
Intervention: Out‐In technique, metal cortical fixation on the femur and tibia
Number of subjects: 45
Study: 21462363

Group type: EXPERIMENTAL
Intervention: Web-based C-ACT
Number of subjects: 173

Group type: COMPARATOR
Intervention: Paper-based C-ACT
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Web-based ACT
Number of subjects: 173

Group type: COMPARATOR
Intervention: Paper-based ACT
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Web-based version preference
Number of subjects: 173
Study: 19330567

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 91

Group type: COMPARATOR
Intervention: Oral iron sulphate
Number of subjects: 91
Study: 17194858

Group type: EXPERIMENTAL
Intervention: High-intervention group
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Moderate-intervention group
Number of subjects: 1614

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1614
Study: 15173775

Group type: EXPERIMENTAL
Intervention: QBS algorithm
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: BP-SPECT algorithm
Number of subjects: 422

Group type: COMPARATOR
Intervention: QBS
Number of subjects: 422

Group type: COMPARATOR
Intervention: BP-SPECT
Number of subjects: 422
Study: 11465336

Group type: COMPARATOR
Intervention: 20 mL of placebo gel (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mL of 2% lidocaine gel (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mL of 2% lidocaine gel (Group III)
Number of subjects: 60
Study: 9766721

Group type: EXPERIMENTAL
Intervention: Endorectal coil (ERC) at 60, 100, and 140 ml balloon inflation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pelvic phased array (PPA) coil
Number of subjects: 21
Study: 8143427

Group type: EXPERIMENTAL
Intervention: Fed state (after a meal containing 80 g of fat and 80 g of carbohydrate)
Number of subjects: 10
Study: 2974418

Group type: EXPERIMENTAL
Intervention: 5'dFUR (doxifluridine) 2 g.m-2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5'dFUR (doxifluridine) 4 g.m-2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 5'dFUR (doxifluridine)
Number of subjects: 6
Study: 30102652

Group type: EXPERIMENTAL
Intervention: Fluconazole 1200 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not taking fluconazole)
Number of subjects: 0
Study: 27118223

Group type: EXPERIMENTAL
Intervention: Smartphone camera (iPhone 5)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Canon EOS 10D anterior segment camera
Number of subjects: 440
Study: 24901857

Group type: EXPERIMENTAL
Intervention: MPSS plus rhEPO (500 unit/kg on admission and another 500 unit/kg 24 hours later)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MPSS alone (30 mg/kg initially and 5.4 mg/kg every hour till 23 hours if admitted within 3 hours and till 47 hours if recruited within 3-6 hours)
Number of subjects: 30
Study: 23104122

Group type: EXPERIMENTAL
Intervention: Patients with ALS
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: Spouses of ALS patients
Number of subjects: 2394
Study: 22010243

Group type: EXPERIMENTAL
Intervention: Mannan-oligosaccharides (MOS) 0.5%
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (PM) 0.1%
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Combined MOS and PM (SYN)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control (Corn-based diet without supplementation)
Number of subjects: 250
Study: 18926059

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice a day for 6 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 16408169

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac suppository
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Diclofenac group
Number of subjects: 228
Study: 14524654

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (Xyrem)
Number of subjects: 140000
Study: 10716359

Group type: EXPERIMENTAL
Intervention: Lund and Browder charts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rule of Nine's diagrams
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Burn experience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Burn shape and location
Number of subjects: 0
Study: 8956025

Group type: EXPERIMENTAL
Intervention: DHEAS levels
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Alcohol consumption, reproductive status, body composition, HDL3 levels
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Sex and age
Number of subjects: 564
Study: 1340107

Group type: EXPERIMENTAL
Intervention: Polyurethane (PU) catheters
Number of subjects: 300

Group type: COMPARATOR
Intervention: Polyethylene (PE) catheters
Number of subjects: 300
Study: 2860283

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg in soft gelatine capsule
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg in uncoated tablet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31374208

Group type: EXPERIMENTAL
Intervention: Elastance-directed indwelling pleural catheter (EDIT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard care (Talc slurry pleurodesis, TSP)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PEL assessment during large-volume thoracentesis
Number of subjects: 31
Study: 28783865

Group type: EXPERIMENTAL
Intervention: Capsule A (4 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Capsule B (4 mg)
Number of subjects: 20
Study: 27310949

Group type: EXPERIMENTAL
Intervention: Lowest TA-SUA group (<5.5 mg/dL)
Number of subjects: 1738

Group type: COMPARATOR
Intervention: Middle 3 TA-SUA groups (5.5-8.4 mg/dL)
Number of subjects: 1738

Group type: COMPARATOR
Intervention: Highest TA-SUA group (≥8.5 mg/dL)
Number of subjects: 1738
Study: 25085225

Group type: EXPERIMENTAL
Intervention: SmartQuit (ACT application)
Number of subjects: 196

Group type: COMPARATOR
Intervention: QuitGuide (NCI application)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: SmartQuit (ACT application) among low acceptance of cravings
Number of subjects: 196

Group type: COMPARATOR
Intervention: QuitGuide (NCI application) among low acceptance of cravings
Number of subjects: 196
Study: 22718556

Group type: EXPERIMENTAL
Intervention: 0.4 µg/kg/min PGE(2) (Prostin(®)E2, dinoprostone)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19164498

Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ethanol (maintained at 0.6 per thousand for 3 h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coadministration of MDMA and ethanol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17392551

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (32 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16353319

Group type: EXPERIMENTAL
Intervention: 1 mg 17beta‐E2/0.125 mg TMG
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1 mg 17beta‐E2/0.5 mg NETA
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2 mg 17beta‐E2/1 mg NETA
Number of subjects: 100
Study: 12072873

Group type: EXPERIMENTAL
Intervention: Newborn Individualized Developmental Care and Assessment Program (NIDCAP)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 321
Study: 9786602

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (nisoldipine or benidipine)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (ACEI) (captopril or imidapril)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Beta-receptor blockers (arotinolol or bisoprolol)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: All antihypertensive agents
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: ACEI
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Arotinolol and bisoprolol
Number of subjects: 86
Study: 7665814

Group type: EXPERIMENTAL
Intervention: Current medical therapy for severe ulcerative colitis
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Current medical therapy for severe Crohn's colitis
Number of subjects: 374
Study: 2764289

Group type: COMPARATOR
Intervention: Room air for 10 min after arrival in the RR
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 35% O2 for 10 min after arrival in the RR
Number of subjects: 209

Group type: COMPARATOR
Intervention: Room air for 10 min at 20 min after arrival in the RR
Number of subjects: 209

Group type: COMPARATOR
Intervention: Room air for 10 min at 1 hr after arrival in the RR
Number of subjects: 209
Study: 29164377

Group type: EXPERIMENTAL
Intervention: 3.25 mg/day DHEA
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 6.5 mg/day DHEA
Number of subjects: 345

Group type: COMPARATOR
Intervention: Plain moisturizer (PM)
Number of subjects: 345
Study: 28935079

Group type: EXPERIMENTAL
Intervention: BRS with post-dilatation
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: BRS without post-dilatation
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: EES with post-dilatation
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: EES without post-dilatation
Number of subjects: 191

Group type: COMPARATOR
Intervention: BRS
Number of subjects: 191

Group type: COMPARATOR
Intervention: EES
Number of subjects: 191
Study: 25194884

Group type: EXPERIMENTAL
Intervention: beclomethasone/formoterol (100/6 μg) bid
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (160/4.5 μg) bid
Number of subjects: 22
Study: 23088925

Group type: EXPERIMENTAL
Intervention: Coping and communication intervention
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Supportive counseling intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 20492392

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound-guided embryo transfer
Number of subjects: 186

Group type: COMPARATOR
Intervention: Transvaginal ultrasound-guided embryo transfer
Number of subjects: 186
Study: 17581531

Group type: EXPERIMENTAL
Intervention: sustained‐release bupropion 150 mg twice daily
Number of subjects: 151

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 151
Study: 17121524

Group type: EXPERIMENTAL
Intervention: l-thyroxine (low-TSH group, 13 patients)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: l-thyroxine plus placebo (euthyroidism group, 12 patients)
Number of subjects: 25
Study: 14636939

Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Sharp Curettage
Number of subjects: 163
Study: 10807468

Group type: EXPERIMENTAL
Intervention: 2 g vitamin C (single dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 g vitamin C daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitroglycerin-mediated dilation
Number of subjects: 20
Study: 8632572

Group type: EXPERIMENTAL
Intervention: 10.8 mg goserelin depot, administered every 12 weeks
Number of subjects: 195

Group type: COMPARATOR
Intervention: 3.6 mg goserelin depot, administered every 4 weeks
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 10.8 mg goserelin depot
Number of subjects: 195
Study: 1520646

Group type: EXPERIMENTAL
Intervention: IV streptokinase prehospital (MCCU group, n = 43)
Number of subjects: 145

Group type: COMPARATOR
Intervention: IV streptokinase in hospital (hospital group, n = 102)
Number of subjects: 145
Study: 6402355

Group type: EXPERIMENTAL
Intervention: 10 mg cellulose bound nitroglycerin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20 mg cellulose bound nitroglycerin
Number of subjects: 40

Group type: COMPARATOR
Intervention: 40 mg sustained release isosorbide dinitrate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30633722

Group type: EXPERIMENTAL
Intervention: Belatacept infusions
Number of subjects: 5
Study: 28253012

Group type: EXPERIMENTAL
Intervention: Self-enhancement before completing a creativity task
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Self-enhancement before completing a pain-inducing cold-pressor task
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Self-enhancement relevant to the task
Number of subjects: 5

Group type: COMPARATOR
Intervention: Self-enhancement
Number of subjects: 5
Study: 26271839

Group type: EXPERIMENTAL
Intervention: Atropine 0.01%
Number of subjects: 400

Group type: COMPARATOR
Intervention: Atropine 0.1%
Number of subjects: 400

Group type: COMPARATOR
Intervention: Atropine 0.5%
Number of subjects: 400
Study: 24912568

Group type: EXPERIMENTAL
Intervention: Web-based appointment systems (WAS)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Traditional appointment methods (queuing)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Alternative forms of appointment booking systems suggested by doctors
Number of subjects: 1000

Group type: COMPARATOR
Intervention: On-the-spot appointment option suggested by non-associated professors
Number of subjects: 1000
Study: 22044557

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 19561259

Group type: COMPARATOR
Intervention: Conventional balloon method (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clamp method (clamp group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Drip infusion for VCUG
Number of subjects: 80
Study: 16771895

Group type: EXPERIMENTAL
Intervention: Matched interventions (information conditions designed to increase positive outcome expectations, decrease negative outcome expectations, or increase self-efficacy)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Mismatched interventions
Number of subjects: 481
Study: 14647133

Group type: EXPERIMENTAL
Intervention: Sustained-release oxycodone (CRO)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sustained-release morphine (CRM)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of morphine and oxycodone
Number of subjects: 26
Study: 10756544

Group type: EXPERIMENTAL
Intervention: Alginate gel beads prepared with low molecular size alginate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alginate gel beads (general)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial sustained-release tablet (Carvisken)
Number of subjects: 0
Study: 8930425

Group type: EXPERIMENTAL
Intervention: Ceftibuten oral suspension 9 mg/kg once daily (maximum dose, 400 mg/d) for 10 days
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cefprozil oral suspension 15 mg/kg twice daily (maximum dose, 1000 mg/d) for 10 days
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cefprozil
Number of subjects: 205
Study: 1473854

Group type: EXPERIMENTAL
Intervention: Modified Release (MR) formulation of diltiazem (60 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Modified Release (MR) formulation of diltiazem
Number of subjects: 8

Group type: COMPARATOR
Intervention: Immediate Release (IR) formulation of diltiazem (60 mg)
Number of subjects: 8